Toll-like receptors in regulatory T cells of patients with head and neck cancer

Archives of Otolaryngology - Head and Neck Surgery

Volumn 136, Issue 12, 2010, Pages 1253-1259

  Wild, Clarissa Anni ^a   Brandau, Sven ^a   Lindemann, Monika ^a   Lotfi, Ramin ^b   Hoffmann, Thomas K ^a   Lang, Stephan ^a   Bergmann, Christoph ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 60; LIPOPOLYSACCHARIDE; NEUTRALIZING ANTIBODY; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 9;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNITY, CELLULAR; MALE; MIDDLE AGED; PHENOTYPE; RETROSPECTIVE STUDIES; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650849488     PISSN: 08864470     EISSN: 1538361X     Source Type: Journal    
DOI: 10.1001/archoto.2010.195     Document Type: Article

References (25)

1. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl JMed. 2001;345(26):1890-1900.
2. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371(9625):1695-1709.
3. Whiteside TL. Immunobiology of head and neck cancer. Cancer Metastasis Rev. 2005;24(1):95-105.
4. Young MR. Protective mechanisms of head and neck squamous cell carcinomas from immune assault. Head Neck. 2006;28(5):462-470. (Pubitemid 43673082)
5. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003;3(3):253-257.
6. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523-532.
7. Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer. 2005;92(5):913-920. (Pubitemid 40462639)
8. + T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13(21):6301-6311.
9. Bergmann C, Strauss L, Wang Y, et al. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res. 2008;14(12):3706-3715.
10. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1(2):135-145.
11. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004;5(10):987-995. (Pubitemid 41057715)
12. Pries R, Wulff S, Wollenberg B. Toll-like receptor modulation in head and neck cancer. Crit Rev Immunol. 2008;28(3):201-213.
13. + responder cells by Fasmediated apoptosis. J Immunol. 2009;182(3):1469-1480.
14. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006;203(7):1693-1700.
15. + regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol. 2009;10(7):689-695.
16. + T cells secreting interleukin-10 and transforming growth factor-β1 mediates suppression in the tumor microenvironment. Clin Cancer Res. 2007;13(15, pt 1):4345-4354.
17. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27(45):5904-5912.
18. Szczepanski MJ, Czystowska M, Szajnik M, et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res. 2009;69(7):3105-3113.
19. Netea MG, Sutmuller R, Hermann C, et al. Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J Immunol. 2004;172(6):3712-3718.
20. Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J. Regulatory T cells selectively express Toll-like receptors and are activated by lipopolysaccharide. J Exp Med. 2003;197(4):403-411. (Pubitemid 36278597)
21. Colombo MP, Piconese S. Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer. 2007;7(11):880-887. (Pubitemid 350006256)
22. Lang S, Whiteside TL, Lebeau A, Zeidler R, Mack B, Wollenberg B. Impairment of T-cell activation in head and neck cancer in situ and in vitro: strategies for an immune restoration. Arch Otolaryngol Head Neck Surg. 1999;125(1):82-88.
23. Wang R-F. Regulatory T cells and Toll-like receptors in cancer therapy. Cancer Res. 2006;66(10):4987-4990.
24. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050-1059.
25. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59-73.